deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04848337

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Sponsor: Hoosier Cancer Research Network

Conditions Neuroendocrine Tumors Prostate Cancer Metastatic
Interventions Lenvatinib Pembrolizumab
Updated 16 times since 2021 Last updated: Feb 10, 2026 Started: May 25, 2021 Primary completion: Jan 8, 2025 Completion: Apr 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neuroendocrine Tumors and Prostate Cancer Metastatic, this trial is ongoing. The trial is conducted by Hoosier Cancer Research Network and has accumulated 16 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Oct 2023 · 5 months · monthly snapshot~Oct 2023 – ~Feb 2024 · 4 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshotRecruiting~Mar 2025 – ~Feb 2026 · 11 months · monthly snapshotActive Not Recruiting~Feb 2026 – present · 6 months · monthly snapshotActive Not Recruiting

Change History

16 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Mar 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 11 earlier versions

  1. Oct 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  2. May 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  3. Feb 2023 — May 2023 [monthly]

    Recruiting PHASE2

  4. Nov 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  5. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  6. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  7. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  8. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  9. Nov 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  10. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. May 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoosier Cancer Research Network
  • Merck Sharp & Dohme LLC
  • University of Michigan Rogel Cancer Center
Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations